8-Methoxypso ralen (8-MOP) levels in the blood of vitiligo patients were determined throu gh the use of a reversephase hi gh-performa nce liquid chromato gra phic method . The overall recovery of th e internal standards was 85-94%, with the lower detection limit of 8-MOP at 2 ng. Peak bl ood levels as low as 130 ng/ ml and as hi gh as 3892 pg/ml w ere obtained in patients at 1-3 h following the oral administration of 0.6 mg/kg body weight of Oxsoralen capsules (Elder Pharmaceuticals Co.). These results are consistent with the clinical observation th at m aximum response in phototherapy .is obtained at about 2 h after oral administration of the dru g. Two hours after oral administration of 0.6 mg/ kg of Ox so ra len , 8-MOP levels in th e epidermis, P hotochemothera py, usin g either topical or oraI8-m ethoxypsoralen (S-MOP) and high-intensity long-wave UV radiation (PUV A) , has becom e a successful modality of treatm ent for vitiligo [1] [2] [3] [4] [5] [6] [7] . The m ethod is more effective for treatin g pigmented individuals [S,9]. Over 200 patients with vitiligo have been successfully treated at our Vitili go Center over the past 6-7 yea rs. When a body surface area ofless than 20% is affected, 0.1 % soluti on of Ox sora len is applied topically, fo llowed by irradiation with graduall y in creasing doses of UV A. T he patients w ith over 20% surface involvement are treated w ith oral Oxsoral en ca psules at a dosage of 0.6 mg/kg of body weight, followed by ex posure to g radually increasing dosages of UV A. Approximately 60% of our patients res pond to either to pica l or oral therapy [S,9]. The question that we asked was w h y all patients fail to respond in a uniform fashion , even w hen the affected areas are of similar severity and duration' . We, therefore, developed a method to measure S-MOP in blood and tissue samples using a reverse-phase hi gh-performance liquid chromatographic (HPLC) method and m easured blood S-MOP levels on a number of patien ts at timed intervals. epidermis, 330 ± 20; dermis, 89 ± 16; w hole skin, 379 ± 19. Also detected were 8-MOP levels of 441 ± 22 n g/ ml in aq ueous humor, 166 ± 18 ng/ml in vitreous gel, 355 ± 15 ng/g in lens, and 410 ± 26 ng/g in retin a. These res ults point to the fact that the eyes of the patient must be protected from exposure to sunli ght after psoralen UV trea tment, and that 8-MOP is absorbed in blood unevenly and varies from patient to patient. The fact that only 50-60% of the patients res ponded to psoralen photochem otherapy for vitiligo may be related to the variation of absorption 
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SUBJECTS, MATERIALS, AND M ETHODS
Patients Blood 8-MOP levels of 36 adult patients (20 males and 16 females) w ere determined afte r written informed consents were obtain ed. Ten-milliliter blood sa mples were drawn prior to oral administration of 0.6 m g/kg body weight of Oxsoralen capsul es. After drug ingestion bl ood samples were drawn at ho url y intervals up to 4 h and at 24 h. All patients invo lved in this stud y fasted overnight prior to the morning of medication and draw ing of blood sa m pIes.
Animals G uinea pigs were used as an an imal m odel in this stud y for photobiologic experim ents. In additio n, the guinea pig was used for meas urem en ts ofS-MOP in whole skin , epidermis, dermis, o phthalmic fluid s, lens, and retina 2 h after oral administration of8-MOP (0. 6 m g/kg of body w eight) in corn oil. H air was removed from the white areas of spotted guinea pigs and the areas were marked into 2-cm squares. Each square was used for application of 0. 1 ml of 0.1% S-MOP, 0. 1 ml of propylene glycolethanol mixture (as a blank), and 0. 1 ml of the material extracted from blood of patients obtained 2 h after the dru g administration . All topica l applica tions were made in triplicate. Thirty minutes after applicati on , the animals were exposed to a high-intensity 0022-202X/86/S03.50 Copy ri ght © 1986 by The Society for Investiga tive Dermatology , Inc.
(UV A) source (Psoralite, Elder Pharmaceuticals Co.). The total dose applied was 1.2J/cm 2 . Phototoxi c responses were observed at 24, 4S, and 72 h .
Materials Crystalline S-methox y p soralen and trimeth y lpsoralen were o btai n ed from Sigma C h emical Co., St. Louis, Misso uri . O xsoralen ca p sules and 1 % Oxsoralen lotio n were o btained from Elder Ph arma ce utica ls, Brya n , Ohio. A cetonitrile, HPLC grade and all other anal y tical-g rad e solvents and che mica ls were obtained from Fisher S cientific Co., Silver Spring, M ary land .
Assay For extracti o n o fS-MOP from blood , fluids , and tissu e homogenates, a 2.0-ml aliquot (or less for ophthalmic fluids) was mixed with 5.0 ml of 0 .05 M ace tate buffer, pH 3.5 in a 50-ml stop p ered Pyrex tube. Sixteen millilite rs of eth yl e ther were add ed at room temperature and tubes we re cap ped . The mi x ture was sh aken on a reciprocating sh aker for 10 min under a hood at 70-S0 s trokes/ min . After centrifuga tion for 10 min at 1020 g, 10 ml of organic layer were transferred to a scintillation vial and the solvent was eva porated to dryn ess und er a stream of dry nit rogen gas. Prior to HPLC analysis , the dry residue was reconstituted in 50 J.LI of a bso lute ethanol , and 10 J.LI we re injected on the chromatographic co lumn. For the meas urem ents ofS-MOP levels in tissues, th ese were homogeni zed in 0.05 M acetate buffer (pH 3.5) and the drug was extracted as d escribed above. The ophthalmic fluids were treated like blood for extraction and the m eas urem ents ofS-MOP. 
Analytical Standards and Preparation of Calibration
Curves A stock solution ofS-MOP was prepared by dissol vi ng 100 mg of analytical grade crystalline S-MOP in 10 ml of absolute e thanol. Suitable dilution of this standard, h aving S-MOP concentration of 1 m g/ ml , was also prepared in ab solute ethanol. A series of further dilutions was m ad e from the latter , so that 10 J.LI (i nj ected into th e column) contained 2, 5, 10, 15, and 20 n g of S-MOP . For recovery studies, enough S-MOP was added to 2.0 ml of blood sa mples so that the final concentrations in blood were 2, 5 , 10, 20, and 30 ng/ ml. The drug w as then extracted from each sample as outlined in the assay method .
RESULTS
The re ten tion time for S-MOP was S.O min which, with the retention time of 16.5 min for th e TMP, was used as an internal standard . Table I shows th e rel ationship between th e peak h eig hts in cm and th e amounts ofS-MOP (in n g ) inj ected onto the c11ro- Table I 32  516  870  480  226  0  36  782  642  662  182  56  28  85  101  130  95  35  45  3730  3892  490  107  0  39  309  3357  385  59  0  35  392  336  230  108  25  27  357  336  225  116  0  46  288  398  480  2 16  0  46  423  468  395  320  0  23  558  880  656  lI S  0  29  468  566  289  198  20  48  1390  2508  337  166  12  52  1087  1567  358  172 Ten milliliters of blood were drawn from each subject in heparinized tube prior to ora l administration of 0.6 mg/kg OxsoraIcn capsu les. After the drug intake, 10 ml of blood were drawn at hourl y interva ls up to 4 h and then at 24 h. Extraction and an alys is of 8-M OP is described in Sl/bjects, Materials, alld Methods. Each resu lt was obtained by averaging duplica te assays. All predrug blood samples were neg-
8-MOP
matog raphic column. Each point was es tablish ed from an average of7 determinations. A s seen in Table I , a fa irl y linear relationship was obtained from external stand ard solutions .
The amounts of S-MOP add ed to and recovered from blood varied from S3-95 %. When 5 .0 n g were added , per ml of bloo d , 4.15 ± 0.6 n g (83%) were recovered . Similarly , for 10.0 n g, 15 .0 n g, and 20.0 n g S-MOP add ed per ml of blood , the res pective recoveri es were 9. 10 ± 0.5 (91%),14.25 ± 0.9 (95 %), and 17.20 ± 2.0 (S6%) .
Blood S-MOP levels were d etermin ed at different times after oral administratio n (of 0.6 m g/ k g body weight of the dru g) and the res ults in male subjects are presented in Table II . The corresponding values for female patients are presented in Table III . A s can be seen, wide variations of blood S-MOP levels were 50  120  330  520  128  62  38  126  298  452  155  56  29  238  393  498  230  26  23  305  446  338  280  11 5  40  338  609  556  235  12  47  414  659  388  166  0  25  512  738  439  208  0  46  250  586  452  333  123  48  382  296  487  400  68  52  250  380  406  239  59  26  633  121 7  830  236  36  30  136  288  493  11 5  0  35  322  659  652  219  0  28  423  1360  666  189  0  38  325  296  460  299  20  55  369  455  380  154  16 Ten milliliters of blood were drawn from each subject in heparinized tube prior to ora l administration of 0.6 mg/kg Oxsoralen ca psules. After the drug intake, 10 ml of blood were drawn at hourly intervals up to 4 h and then at 24 h. Extraction and analysis of 8-MOP is described in S"bjcas, Ma te,.ials, alld Methods. Each result was obtained by averaging duplicate assays. All predrug blood sa mples were negative . observed. However, the results indicate that peak blood 8-MOP levels occurred most often at 2 h after ingestion of the drug, except for a few cases . One of the 20 male patients absorbed the drug rather poorly (patient 3); 6 of the 20 male patients obtained peak 8-MOP levels of over 800 ng / ml, and 2 of the 6 patients reached peak levels of over 3000 ng/ml. In addition, 2 of the male patients obtained blood psora len levels of 1500-2500 ng/ml. The peak blood levels of the other male patients were between 755 and 336 ng/ml. Table III shows that 7 of the 16 female patients obtained peak blood levels at 3 h, although 8-MOP levels at 2 h were sufficiently high in these patients. Two of the 16 female patients obtained peak 8-MOP blood levels of over 1000 ng/ml and 14 of 16 female patients obtained peak 8-MOP levels of 406-738 ng/ml.
Presented in Table IV are the 8-MOP levels in eye tissues, ophthalmic fluids, and skin tissues determined 2 h after oral administration (0.6 mg/kg) to the guinea pigs. Aqueous humor was drawn from the anterior chamber of the eyes with a tuberculin syringe. Vitreous gel, retina, and lens were dissected out. The extraction and determination of 8-MOP in these fluids were performed by the same assay method as for blood . The drug levels m retma, lens , aq ueous humor, skin, and epidermis were higher as compared with the level in the dermis . The concentration in aq ueous hun:or, lens, and retina was more than twice as high compared With that in vitreous gel. Similarly, the level in epidermiS was more than 3 times higher than that of the dermal level of the drug.
In order to determine whether the compound, extracted from the blood and measured by HPLC, was photobiologically active, experiments were conducted using the guinea pig as the test animal. The material extracted from patients' blood was pooled, evaporated to dryness, and reconstituted in 0.5 ml of a mixture of 30% propylene glycol, 69% ethanol, and 1 % acetone; 0.1 ml of the solvent, as well as the extracted material and 0. The m ethods used to help with the tentative identification of the compound extracted from blood were thin-layer chromatography' and cochromatography with authentic 8-MOP on thinlayer plates in 2 separate solvents (900: 10 benzene-ethyl acetate by vol and ethylaceta te : chloroform: acetone: methanol: acetic acid, 5: 5: 3: 1 : 1 by vol), as well as by gas-chromatography and mass spectrometric fragmentation pattern. By gas-chromatography, the material from the blood was eluted at an identical position as authentic 8-MOP. The mass spectral fragmentation of the extracted material was also identical to that of authentic 8-MOP producing masses at 216, 188, 173 dalton, etc., by elimination of -co, CH 3 , etc.
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DISCUSSION
By using thin-layer chromatography and scanning fluorometr we reported plasma 8-MOP level of a patient. The peak level It 2 h was 3000 ng/ml [10) . A large number of investigators, us in a variety of methods, reported 8-MOP levels in psoriatric patient~ and normal volunteers [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . The peak blood or plasma 8-MOP levels reported varied widely from as low as 2 ng/ml to as high as 3000 ng/ml [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Our results, as presented here, are generally higher than tho~e reported elsewhere. In general, there was no clear-cut relatIOnship between peak plasma levels, time at which the p<:ak leve~s occurred, the UV A exposure time, and the therapeutic effectiveness. Ideally, patients should receive UV A treatment when epidermal 8-MOP level is highest . This time may be slightly later than the time at which peak blood level is achieved Murata et al [29) studied distribution of [3H)TMP in the ra~ and found that 2 h after oral administration the drug level was of the order of 4.0 J.Lg/ml. Also, we reported significant TMP accumulatIOn m the whole skin and epidermis of the guinea pig [18) . We find now that accumulation of 8-MOP is also high (r.esults III Table IV) 111 th<: whole skin and epidermis of the guinea pig after oral ad!mmstratlon of the drug with a dose comparable. to a dose III patients treated for therapeutic effectiveness. . .A number of reports (30) (31) (32) (33) (34) (35) (36) (37) (38) indicate that photochemotherapy lllitiates cataract formation . Lerman and Borkman [33) demonstrated accumulation of 8-methoxypsoralen in the ocular lens of the rat. We also reported significant accumulation of TMP in ocul~r flUids of the guinea pig [18) . Results in Table IV show slgmficant ~ccumulation of 8-MOP in retina, lens, aqueous humor, and vitreous gel of the guinea pig . These results are similar to those reported by Pathak et al [3) and Stern et al [38) , and pomt to the fact that the eyes of the patient must be protected from exposure to additional sunlight after psoralen UV treatment [34] [35] [36] [37] .
In summary, a reverse-phase HPLC method for measurements of 8-MOP in blood, ophthalmic fluids, retina, lens, skin, epid.e~mls, and dermiS has been developed. The lower limit of senSitivity of the metho~ is of th~ order of 2 ng/ml. 8-Methoxy_ ~soralen IS preferentially localized 111 certa111 body fluids and tissues, such as aqueous humor and epidermis. Since aqueous humor, lens, and ophthalmic tissues acquire very high concentratIOns of psoralens for 24 h, protection of the eyes during phototherapy and prevention of exposure to the sunlight for 24 h are extremely important for prevention of blindness.
Since our results appear to be higher than those reported elsewhere, we believe that the reverse-phase HPLC method is more sensitive and would be more useful in correlating clinical responses 111 the photochemotherapy of skin diseases with blood levels of 8-MOP.
It also becomes necessary to determine blood psoralen levels of 40% nonresponding patients at timed intervals to determine whether the drug is absorbed sufficiently and at what time after or~1 administration. In case of poor blood 8-MOP levels, expected Skll~ levels may also be very low and, hence, little or no phototoxIcity or melanogenesIs will occur. In slIch instances a better method of drug delivery at the target organ must be designed for the nonresponders.
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